作者:Linda M. Haugaard-Kedström、Louise S. Clemmensen、Vita Sereikaite、Zeyu Jin、Eduardo F. A. Fernandes、Bianca Wind、Flor Abalde-Gil、Jan Daberger、Maria Vistrup-Parry、Diana Aguilar-Morante、Raphael Leblanc、Antonio L. Egea-Jimenez、Marte Albrigtsen、Kamilla. E. Jensen、Thomas M. T. Jensen、Ylva Ivarsson、Renaud Vincentelli、Petra Hamerlik、Jeanette Hammer Andersen、Pascale Zimmermann、Weontae Lee、Kristian Strømgaard
DOI:10.1021/acs.jmedchem.0c00382
日期:2021.2.11
Despite the recent advances in cancer therapeutics, highly aggressive cancer forms, such as glioblastoma (GBM), still have very low survival rates. The intracellular scaffold protein syntenin, comprising two postsynaptic density protein-95/discs-large/zona occludens-1 (PDZ) domains, has emerged as a novel therapeutic target in highly malignant phenotypes including GBM. Here, we report the development
尽管最近在癌症治疗方法方面取得了进步,但高度侵袭性的癌症形式(例如胶质母细胞瘤(GBM))的存活率仍然非常低。细胞内支架蛋白syntenin,包括两个突触后密度蛋白95 / discs-大/ zona occludens-1(PDZ)域,已成为包括GBM在内的高度恶性表型的新型治疗靶点。在这里,我们报道了一种新型的,高效的,Syntenin代谢稳定的肽抑制剂KSL-128114的开发,该抑制剂以纳米摩尔亲和力结合Syntenin的PDZ1域。KSL-128114具有抗人血浆和小鼠肝微粒体降解的能力,并且对syntenin具有全局PDZ域选择性。X射线晶体结构揭示了KSL-128114与syntenin PDZ1以扩展的非规范结合模式相互作用。用KSL-128114处理对原发性GBM细胞活力具有抑制作用,并在患者来源的异种移植小鼠模型中显着延长了生存时间。因此,KSL-128114是一种新的